Journal
EXPERT REVIEW OF CARDIOVASCULAR THERAPY
Volume 10, Issue 1, Pages 13-25Publisher
TAYLOR & FRANCIS INC
DOI: 10.1586/ERC.11.166
Keywords
atenolol; carvedilol; heart failure; hypertension; metoprolol; myocardial infarction
Categories
Ask authors/readers for more resources
beta-blockers are a standard of care in many clinical settings such as acute myocardial infarction, heart failure and patients at risk for a coronary event. However, not all beta-blockers are the same and they vary in properties such as lipophilicity, metabolic profile, receptor inhibition, hemodynamics, tolerability and antioxidant/anti-inflammatory effects. It has been unclear whether these differences affect outcomes or if one beta-blocker should be preferred over another. This review will summarize the properties of metoprolol, atenolol and carvedilol, as well as comparative experimental and clinical trials between these agents. We will provide compelling evidence of why carvedilol should be a first-line beta-blocker and why it offers many advantages over the beta 1-selective beta-blockers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available